LLY - Eli Lilly and Company Pick

a sunset view of a mountain range with clouds in the sky

Research brief

Oct 20, 2026 Afternoon

05:00 PM UTC

Eli Lilly and Company LLY low

LLY

Conf. Low

Pick Pr. $1285.09

Stop Pr. $1255.02

Curr. Pr. $1283.66

Change -0.11%

Rem. Days 7

Summary

Buy Eli Lilly (LLY) now — Momentum, Low confidence. This preserves the decider's selection, not a promise of market outperformance. The original research entry was $1,291.800048828125 at 14:06 ET on October 20; the independent publication quote is $1,288.0350341796875 at 14:28 ET. Both are indicative observations, not fills. finance.yahoo
Decider estimates: seven-day net policy return +0.5121%, versus −0.0522% for matched-horizon SPY; excess +0.5643 percentage points. Deducting the 1.6-point forecast-uncertainty allowance leaves −1.0357 points of adjusted excess. The positive absolute-return gate passes before uncertainty; the adjusted comparison is unfavorable, not hidden.
Fresh evidence, limited immediate economics: Lilly's October 19 pediatric Omvoh release reported the SHINE-2 primary endpoint met. It does not establish an approved pediatric indication or incremental cash during this trade. investor.lill
Risk plan: authored stop $1,255, conditional stop-exit estimate $1,240, T1 $1,330. At the original research entry, the actual full-position profit barrier is $1,360.5599609375, not T1. These are decider estimates and policy calculations, not source forecasts or guaranteed fills.
Clock and event caveats: the frozen forecast runs October 20, 14:06 ET → October 27, 14:06 ET. Actual entry and maturity have not been supplied; execution must persist exactly seven calendar days from actual entry. In-window oncology presentations include weekend exposure; the issuer's earnings call is October 29 at 10:00 EDT, outside the frozen interval. investor.lill investor.lill

Why Now

The current edge is relative-strength momentum with newly released clinical franchise evidence, not a claim that one study explains the whole rally. First public disclosure of the one-year pediatric SHINE-2 results was October 19, 2026; an exact first-release clock was not established. The open-label, single-arm study reported 81% clinical response after 12-week induction and, among induction responders, 50% clinical remission at week 52. Lilly stated that it planned regulatory submissions. The 50% figure must not be represented as remission among all original entrants. investor.lill

Decider interpretation: these results can improve expectations for Omvoh's franchise breadth, but the handoff does not quantify incremental pediatric sales, margins, cash, or a seven-day estimate upgrade. The new information is the one-year result, not a new approval. The mechanism for this holding period is further investor repricing of an already profitable business, not receipt of new pediatric launch revenue.

For the completed September 22–October 19 window, the price feed reports LLY +6.00%, XLV +3.39%, and SPY −0.89%: LLY's matched excess was 2.61 points versus XLV and 6.89 points versus SPY. These are historical comparisons, not causal event attribution or a forward return forecast. finance.yahoo

Publication check, October 20: the fresh current constituent list identifies LLY, Lilly (Eli), Health Care/Pharmaceuticals, matching the quoted issuer. This was an independently fetched current public list, not a new index-sponsor certification. en.wikipedia. The 14:28 quote was approximately 0.2915% below the 14:06 research entry—an author calculation from the two timestamped quotes. The returned completed five-minute bars through 14:25 ET show a continuing fade below phase VWAP, but their lows remain above the decider's $1,260.1700 opening-support reference and $1,255 stop. The overlap is a scoped recheck, not proof of unseen trades or an actual event-anchored VWAP base. finance.yahoo

No newly observed structural invalidation is established by that check. The numerical ranks and scenario returns below remain the decider's 14:03–14:06 research freeze, not a newly synchronized ranking at the publication quote. The original entry, target and probabilities are retained so the forecast is auditable; they are not silently re-estimated from a better quote. Any material subsequent support, price-path or event change requires an upstream re-freeze rather than writer substitution.

Business And Market Context

Lilly develops and sells pharmaceuticals, including cardiometabolic products Mounjaro and Zepbound, immunology products including Omvoh, and oncology medicines. The issuer's August 5 second-quarter release reported $22.974 billion revenue, up 48%, with volume up 60% and price down 13%; gross margin was 85.8%. These are older operating foundations, not fresh October 20 earnings news. investor.lill

That release reported EPS of $7.94, or $8.38 non-GAAP, including a $3.03 acquired in-process R&D charge. Full-year revenue guidance was $85–87 billion and non-GAAP EPS guidance $35.50–36.50. The underlying EPS-midpoint improvement of $2.78 was more than offset by that charge; the $250 million Jardiance milestone must not be treated as recurring growth. investor.lill Analysis: volume-led expansion and profitability support resilience, while pricing erosion and nonrecurring items weaken a simple “all growth converts to recurring earnings” argument.

At June 30, 2026, the supplied filing evidence showed $8.950 billion cash, $54.908 billion debt, and $10.1 billion unused bank facilities. First-half operating cash flow was $16.023 billion, versus $5.259 billion capital expenditure and $9.805 billion acquisition cash spending. The decider calculated net debt of $45.958 billion, a current ratio of 1.355, and operating cash flow less capex of $10.764 billion. These are dated balance-sheet observations and simple calculations, not an exhaustive current financing or covenant clearance. investor.lill

The 14:28 publication profile reports approximately 43.24× trailing earnings and 27.28× forward earnings. Forward multiples depend on provider estimates and do not establish a verified revisions trend. finance.yahoo Analysis: this is a premium-growth momentum trade, not a cheap-valuation thesis; disappointment can compress the multiple despite strong operating results.

The market backdrop is mixed. At 14:06 ET, SPY was $769.4400, below its completed 20-day average 770.833, but above its 50-day 767.3027 and 200-day 722.3267 averages. QQQ remained below its 20/50-day averages, while equal-weight RSP was above its 50-day average. RSP is a participation proxy, not a constituent advance/decline count. finance.yahoo finance.yahoo finance.yaho Secondary-provider snapshots at approximately 13:51 ET, after offset normalization, showed the ten-year yield index equivalent to 5.119% and VIX 17.35; these were not direct Treasury/Cboe verifications. finance.yaho finance.yaho

Decider benchmark estimate: retain 30%/45%/25% endpoint weights on SPY 778.01/770.46/758.79, respectively. The weighted terminal value 769.8075 implies +0.0477616913% price drift from the frozen entry; subtracting 0.10 percentage point friction yields −0.05223830871442506% net. These are uncalibrated seven-day assumptions, not reported market forecasts. No dividend is added: the supplied schedule gives a September 18 ex-date for the October 30 payment and a next ex-date of December 18, so the proposed new buyer is not entitled to the earlier distribution. ssga

The October 27 13:00 ET Federal Reserve H.6/commercial-paper releases precede the frozen 14:06 exit; outcomes are not assumed favorable. Exact dated auction closing time and some other primary macro-release times remain unverified. federalreser bea.gov This common market exposure affects the forecasts and risk assessment; it is not a Lilly-specific binary veto.

Factor Stack

Factor	Source observation	Decider assessment / limitation
Catalyst	October 19 one-year pediatric Omvoh results; planned submissions. investor.lill	Fresh franchise evidence, but no quantified in-window commercial contribution.
Growth and profitability	August 5 Q2 release: 48% revenue growth, 85.8% gross margin; price declined 13%. investor.lill	Strong underlying demand, with price pressure and acquisition-related accounting qualifications.
Valuation and resilience	14:28 profile: 43.24× trailing/27.28× forward P/E; June 30 cash and debt as above. finance.yahoo investor.lill	Premium valuation and sizable net debt contradict an easy rerating; cash generation supports, but does not guarantee, funding resilience.
Momentum	Completed-window XLV/SPY excess of 2.61/6.89 points; October 20 high $1,311.75. finance.yahoo	Historical leadership supports continuation; the intraday fade is the strongest immediate contradiction.
Expert views	The retained October 12 RBC Outperform/$1,500, October 8 Cantor $1,410→$1,440, and October 7 Morgan Stanley $1,419→$1,430 records are longer-horizon targets. benzinga	They are not seven-day targets, evidence of realized buying, or a verified EPS-revision series.
Community / revisions	The retained Stocktwits check contained mixed October 16–19 discussion and an untimestamped bullish widget. stocktwits	Tiny, unrepresentative sample; ambiguous/later posts were excluded. No representative current Reddit/X/YouTube consensus or verified same-basis EPS revisions were established. No sentiment/revision premium is assumed.

Technical derivation, not a provider forecast: the decider's pre-October 19 ATR14 is $37.2056928571, the arithmetic mean of 14 completed true ranges dated September 29–October 16, using max(high−low, |high−prior close|, |low−prior close|); this is not Wilder smoothing. Completed October 19 SMA20/SMA50 were $1,182.536/$1,181.2988. The original entry was approximately 2.937 ATR above SMA20. finance.yahoo

The documented 2.5× pre-event ATR threshold is $93.0142. The decider observed maximum October 20 displacement $71.41 and session range $51.5800, below that threshold; roughly 10% repricing and the specified high-beta failed-breakout rule were not established. Therefore the mandatory post-event-base gate was not triggered in the retained decision. This is not a claim that phase VWAP is event anchored or that a next-session hold has already completed. finance.yahoo

The returned 1.9 million partial-session volume must not be compared directly with a full-day average as proof of accumulation. The handoff identified cumulative/bar-volume inconsistencies, preventing a reliable event-VWAP or institutional-flow claim. Phase VWAP resets by date and market phase; it is not actual release-anchored VWAP. finance.yahoo

Investment Thesis

What must still reprice

Decider estimate: T1 $1,330 rounds the $1,292.65 breakout reference plus the independently calculated pre-event ATR of approximately $37.2057. The breakout reference came from limited visible IBD commentary; the full article was unavailable. It is not an annual consensus price target. investors

At the frozen entry, T1 implies +2.9571%, while the execution policy requires 1.8 times that percentage return, or +5.3228%, for a full-position profit exit:

$1,291.800048828125 + 1.8 × ($1,330 − $1,291.800048828125) = $1,360.5599609375.

The near obstacle $1,297.1899 is separate from both T1 and the later $1,311.75 session high. Those are observed path references; neither replaces the seven-day target. finance.yahoo Decider assumptions: a 55% illustrative chance of clearing $1,311.75, including the nearer obstacle, and approximately 36.36% further first-exit continuation motivate 20% actual-barrier odds. Multiplying these judgments does not make them empirically calibrated.

Frozen policy scenarios

All numbers in this table are decider assumptions or calculations at the original research entry, not source-reported probabilities. The branches are mutually exclusive and total 100%.

First policy outcome	Probability	Conditional gross return / price
Actual full-position profit exit	20%	+5.3227984%; $1,360.5599609375 barrier
Stop exit after confirmation/gap effects	25%	−4.0099123%; estimated mean $1,240
Neither earlier exit; exit at maturity	55%	+1.00% conditional mean

Subtract 0.10 percentage point total adverse-exit friction, once. Expected policy return is 0.20×5.3227984 + 0.25×(−4.0099123) + 0.55×1 − 0.10 = +0.5120816%. Early exits leave cash through the original maturity, with no assumed interest or reinvestment. The authored-stop distance is 2.8487419%; raw T1 reward/risk is 1.0380, and expected return divided by authored-stop risk is 0.1798. These are diagnostics, not independent selection gates.

Opportunity cost and adverse review

The following preserves the full final-gate ranks. Returns are decider estimates/calculations; underlying research quote windows are October 20, 14:03–14:06 ET, not publication-time simultaneous fills.

Rank	Candidate	Base net return	Net excess vs SPY	Uncertainty deduction	Adjusted excess
1	LLY	+0.5121%	+0.5643 pp	1.6 pp	−1.0357 pp
2	XEL	+0.1094%	+0.1616 pp	1.2 pp	−1.0384 pp
3	ZBRA	+0.5882%	+0.6404 pp	1.7 pp	−1.0596 pp
4	WSM	+0.6532%	+0.7055 pp	2.2 pp	−1.4945 pp
5	WDAY	+0.5119%	+0.5642 pp	2.5 pp	−1.9358 pp

Next-best comparison: XEL is viable, not hard-rejected. Its older July 30 operating foundation is not a new October earnings raise, and its quote/history showed extension and less return headroom. investors.xc finance.yaho The decider also penalized rate/funding sensitivity and overlap with the supplied active AEP exposure. LLY's lead is only 0.0027180202230305817 percentage point of adjusted excess—economically tiny and not statistically established. Fresher October 19 evidence and healthcare diversification favor LLY qualitatively; there is no robust measured alpha claim.

ZBRA's higher base return did not compensate for its larger uncertainty budget; the retained history showed repeated overhead supply. WSM's higher base estimate depended more heavily on its +2% surviving time-exit mean. WDAY required further clearance of multiple resistance levels without quantified seven-day AI cash. These are the decider's ranking judgments, not additional hard exclusions. Their full scenario inputs are retained above; source observations are bound in each scenario basis. finance.yaho finance.yaho finance.yaho

Coherent adverse forecast, unchanged entry/stop threshold/T1/horizon/policy: the decider reduced LLY profit-exit odds to 12%, raised stop odds to 33%, retained 55% time exits but lowered their mean to 0%, and lowered conditional stop proceeds to $1,230. A common market setback also reduced SPY's expected net return to −0.3778647373%; it did not assume a simultaneously stronger benchmark simply to worsen relative results.

Decider sensitivity	LLY	XEL, next viable alternative
Base net / net excess	+0.5121% / +0.5643 pp	+0.1094% / +0.1616 pp
Stress net / net excess	−1.0400% / −0.6621 pp	−0.9816% / −0.6038 pp
Minimum uncertainty to cover absolute forecast deterioration	1.5521 pp	1.0910 pp
Declared deduction / covers stress	1.6 pp / yes	1.2 pp / yes
Profit-to-stop probability-shift headroom	5.487152 pp	1.631111 pp
Profit-to-time probability-shift headroom	11.846493 pp	4.834757 pp

For XEL, stress used 15%/34%/51% profit/stop/time odds, a $73.90 conditional stop exit, −0.2% conditional time return, 0.1% friction and the same stressed SPY forecast. Headroom is arithmetic sensitivity, not a prescribed probability haircut or historical frequency; reported rounding differs slightly from full-precision formulas retained in the scenario bases.

Uncertainty interpretation: LLY's 1.6-point deduction covers the identified 1.5521-point adverse deterioration once plus a small residual mean/coverage allowance. It is not ATR/VIX volatility subtracted from expected return, and neither that deterioration nor an inherited benchmark allowance is deducted a second time. Negative stress and adjusted excess remain prominently disclosed; under the governing rule, neither independently vetoes a supported positive base absolute return.

Risks And Thesis Breakers

Strongest contradiction—price behavior versus the assumed continuation. The 14:28 quote and latest completed bars remain below the returned phase VWAP, after a high of $1,311.75. finance.yahoo Decider interpretation: this challenges the 20% actual-barrier probability and +1% surviving time-exit mean. The trade needs additional repricing, not merely preservation of yesterday's fundamentals.
Structural invalidation and delayed exits. The decider chose $1,255 below the October 20 opening support of $1,260.1700, with $1,240 as a conditional mean actual stop exit, near the October 19 low $1,239.10. The supporting lows are price observations; the stop and exit mean are analyst choices. finance.yahoo A broken opening structure is adverse thesis evidence; the actual exit still follows the prescribed confirmation rules, not an invented discretionary intraday sell.
Clinical and weekend gap risk. Lilly's October 18 announcement schedules ESMO for October 23–27, with key presentations October 23–26. Its table labels times “CET”: Sofe-M October 24, 08:30–10:00; postMONARCH October 24, 10:15–11:45; olomorasib October 25, 08:30–10:00; LIBRETTO-531 October 26, 10:15–11:45. Exact abstract availability and CET/daylight-saving ordering remain unresolved. investor.lill The decider did not identify a thesis-dependent binary before the next executable stop window and assumes no favorable unread result. This is scoped evidence, not exhaustive event clearance; adverse weekend news can gap below either modeled stop-exit price.
Valuation, pricing and balance sheet. Premium earnings multiples, falling realized price in the dated Q2 release, acquisition/manufacturing spending and sizable debt are genuine contradictions. finance.yahoo investor.lill investor.lill Analysis: disappointing demand, reimbursement or safety news could overwhelm a modest seven-day expected return. No current solvency failure was established in the supplied review; that is not a guarantee against financing or regulatory surprises.
Evidence and model risk. There is no empirical seven-day first-policy-exit sample, verified current EPS-revision series, representative social consensus, or quantified clinical-to-weekly-cash bridge. Volume inconsistencies limit accumulation claims. These limitations explain Low confidence; confidence is descriptive, not a return gate. Longer-horizon analyst targets and an unverified partnership search lead were not converted into forecast cash.
Portfolio concentration. The supplied portfolio—not an independently accessed account—has 33.75% Financial Services, 16.51% Industrials, 16.48% Technology, 8.43% Utilities, 8.30% Consumer Defensive and 16.53% cash. Its listed active symbols exclude LLY. Analysis using supplied holdings: healthcare adds sector diversity and avoids another utility/AEP-correlated lot, but one stock still adds idiosyncratic and broad-market risk; diversification does not establish positive alpha.

Investment Recommendation

Recommendation: BUY LLY now as a Momentum trade, Low confidence, for exactly seven calendar days. The publication observation is $1,288.0350341796875 at 14:28 ET, October 20, 2026; the retained forecast entry is $1,291.800048828125 at 14:06 ET. Neither is a broker fill. finance.yahoo The expected-return comparison and all probability assumptions remain the original decider freeze; no new selection or optimistic assumption change is made here.

Use the supplied one-slot allocation, 1/12 of the fund, subject to the one-active-lot-per-symbol restriction. This is the user-supplied sizing policy, not an assertion that an order was placed.

Horizon: preserve the frozen reference maturity October 27, 2026, 14:06 ET, a regular-session exit window. nyse Before execution, persist the actual entry and maturity exactly seven calendar days later. For example, an actual October 20 14:28 ET entry matures October 27 14:28 ET, in that regular-session window—not the next opening or a later closing auction. This example is a policy calculation, not a claim of a fill. The original 13:00 scheduled run start was not a verified entry; do not extend any already-live holding if its authoritative clock differs.
Authored stop: $1,255. The trailing 60-minute average must remain below it for 120 minutes before the authored-stop exit qualifies. A momentary price touch does not imply an immediate sale. The conditional modeled actual stop exit is $1,240 before friction, not an assured price or maximum loss.
Hard-loss rule: a 15% loss condition requires ten minutes of confirmation. At the original research entry its threshold is approximately $1,098.030042; actual execution must use actual entry. Confirmation delay, illiquid periods and gaps can produce materially worse proceeds. There is no guaranteed 15% loss cap.
Profit rule: T1 remains $1,330, but the full-position barrier is entry + 1.8×(T1−entry). It was $1,360.5599609375 at the research entry. As a transparent geometry-only illustration, at the 14:28 indicative quote it would be $1,363.57197265625; a lower entry with fixed T1 raises this absolute barrier. That illustration is not a new probability forecast or executable-fill certification. Do not exit or trim merely because T1 is touched.
Execution costs and proceeds: apply 0.1% adverse slippage once, already included in the 0.1% friction assumption. The first valid policy exit governs; otherwise exit at maturity. Hold early proceeds in cash until that original maturity, without assumed interest, discretionary re-entry, new trailing rules or horizon extension.

Bottom line: this is a small positive-base, uncertainty-sensitive trade—not a high-conviction claim of SPY outperformance. The independent publication checks found no observed breach of the selected structural risk levels and retained the known clinical-calendar caveats. Actual fill/clock persistence and any material quote, support or event change must be reconciled before execution; the very narrow research ranking should not be mistaken for a fresh, statistically robust publication-time comparison. The separate VOO-versus-Gold-cash branch is not applicable because the authoritative stock decision is BUY, not audited N/A.